ShajiniThe National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million women in the UK affected by this chronic condition. Clinical trials have substantiated that linzagolix effectively reduces both dysmenorrhea and non-menstrual pelvic pain in … Read more
A validated capacity assessment tool designed to strengthen orthopedic surgery capabilities in low- and middle-income countries (LMICs) has demonstrated excellent reliability and practical utility in pilot testing, addressing a critical healthcare disparity that affects millions globally. The Capacity Assessment Tool for Orthopedic Surgery (CAT-os) provides systematic evaluation frameworks for surgical outreach programs targeting regions where … Read more
Randox Laboratories has secured FDA de novo clearance for its ConcizuTrace ELISA companion diagnostic, designed to quantify plasma concentrations of Novo Nordisk’s recently approved hemophilia treatment Alhemo (concizumab-mtci). The regulatory milestone comes just weeks after Alhemo received FDA approval in December 2024 as a once-daily prophylactic injection for adults and pediatric patients 12 years and … Read more
Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the … Read more
CND Life Sciences reported baseline results from its NIH-sponsored Syn-Sleep Study, demonstrating the Syn-One Test’s ability to detect phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (iRBD). The 24-month longitudinal study enrolled 80 participants across 11 US sites, representing a critical validation step for cutaneous biomarker detection in prodromal neurodegenerative … Read more
Stryker Completes $3.1 Billion Acquisition of Inari Medical, Entering High-Growth Venous Thrombectomy Market Stryker Corporation (NYSE: SYK), a global leader in medical technology, has completed its acquisition of Inari Medical, Inc. (NASDAQ: NARI), a pioneering developer of devices for venous thromboembolism (VTE) treatment. This strategic $3.1 billion acquisition marks Stryker’s entry into the rapidly growing … Read more
On Jan. 27, 2025, Pure Health has agreed to acquire a 60% stake in Hellenic Health Care Group (HHG). The transaction values. 2.3 billion at USD. Pure Health is the largest healthcare group in the Middle East. Hellenic Health Care Group is the largest private healthcare provider in Greece and Cyprus. Pure Health Partnering with … Read more
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more
On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more
In early 2025, significant developments across the biopharmaceutical and medical device sectors shaped the healthcare landscape. Stryker’s $4.9 billion acquisition of Inari Medical, Transcarent’s $621 million deal for Accolade, and several FDA designations for investigational treatments, such as Johnson & Johnson’s nipocalimab, highlight industry advancements. Medicare’s rescinding of coverage for certain cancer genetic tests and … Read more